Back to top
more

CONMED (CNMD)

(Real Time Quote from BATS)

$73.39 USD

73.39
321,605

-1.37 (-1.83%)

Updated Nov 8, 2024 03:45 PM ET

After-Market: $73.43 +0.04 (0.05%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Dental Supplies

Zacks News

Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4

Cryolife (CRY) revenues increase year over year across all geographies and major segments.

Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates

Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.

Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

Bio-Techne (TECH) sees increase in revenues across key segments.

Here's Why Investors Should Buy CONMED (CNMD) Stock Now

CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.

DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates

DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.

Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates

Medidata (MDSO) gains from solid segmental performance in Q4.

Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong

Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.

STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates

STERIS (STE) continues to gain from strength in all business segments in Q3.

IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up

IRADIMED (IRMD) reports growth across all operating segments and geographies

Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up

Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.

Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss

Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.

Cardinal Health (CAH) Surges: Stock Moves 6.8% Higher

Cardinal Health (CAH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates

LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.

Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View

Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.

Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3

Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.

Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip

Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.

Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates

Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.

Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss

Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.

Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster

Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.

Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates

Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.

Omnicell Solid on Geographic Expansion Amid Stiff Competition

Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.

PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y

PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.

McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View

McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.

Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top

Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.